Announcements
- Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
- Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
- Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
More ▼
Key statistics
As of last trade Aligos Therapeutics Inc (5WK:FRA) traded at 0.523, 3.56% above its 52-week low of 0.505, set on Dec 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.523 |
---|---|
High | 0.523 |
Low | 0.523 |
Bid | 0.537 |
Offer | 0.559 |
Previous close | 0.524 |
Average volume | 4.65k |
---|---|
Shares outstanding | 78.11m |
Free float | 59.58m |
P/E (TTM) | -- |
Market cap | 45.30m USD |
EPS (TTM) | -1.51 USD |
Data delayed at least 15 minutes, as of May 28 2024 07:17 BST.
More ▼